Drug Profile


Alternative Names: Acetorphan; Hidrasec; Racemic acetorphan; Tiorfan; Tiorfast; Tiorfix

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioprojet
  • Developer Abbott Laboratories; Bago; Bioprojet; Ferrer; GlaxoSmithKline; Leti; Nordic Drugs; Takeda
  • Class Antidiarrhoeals; Antisecretories; Benzyl compounds; Esters; Small molecules; Sulfhydryl compounds; Sulfur amino acids
  • Mechanism of Action Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diarrhoea

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Diarrhoea(In volunteers, In adults) in France (PO, Suspension)
  • 05 Oct 2017 Bioprojet completes a phase I trial in Healthy children in France (PO, Suspension) before October 2017 (EudraCT2017-000278-13)
  • 11 Apr 2017 Phase-I clinical trials in Diarrhoea (In children, In volunteers) in France (PO, Suspension) (EudraCT2017-000278-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top